Assessing Openness to Usage of Biosimilars

Project: Research project

Project Details


The goal of this project is to better understand the resistance to biosimilars, both from the physician and patient sides. Our approach is comprehensive, taking into account many different types of potential influences on resistance, from cost and physician willingness to prescribe, to patient engagement, behavioral traits, and sociodemographic factors. We will conduct a study with the following aims: Aim 1: Identify the elements of differentiation in patient response to biosimilars. Aim 2: Conduct large-scale, survey-based exploratory data collection to identify patient psychosocial factors, contextual factors, and aspects of biosimilars that are associated with acceptance of biosimilars. Aim 3: Develop a conceptual model of biosimilar acceptance that integrates the findings from Aims 1 & 2 and sets forth an agenda for subsequent research, including the development of a patient-reported measure of openness to biosimilars or the development of guidelines for patient-physician communication on biosimilar use, or tools to address the nocebo effect among patients using biosimilars.
Effective start/end date9/1/188/31/21


  • Pfizer Inc. (Agmt 7/24/18)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.